Access cutting-edge dlbcl treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access dlbcl specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related dlbcl treatment provided free
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least
Sponsor: Miltenyi Biomedicine GmbH
Check if you qualify for this dlbcl clinical trial in Chicago, IL
If you're searching for dlbcl treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced dlbcl specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.